Sunyue He

Sunyue He

Auto-generated profile, based on publicly available information

Sunyue He

Department of Endocrinology and Metabolism, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2016 in Journal of Neurological Surgery Part A: Central European Neurosurgery
Verified
Journal Article
Closed access
PDF file
CLCai Lin
Cai Lin
XWXinling Wang
Xinling Wang
XLXiangwei Lin
Xiangwei Lin
SHSunyue He
Sunyue He
YLYunfeng Liu
Yunfeng Liu
XLXu Luo
Xu Luo
Objective The closure of chronic wounds after skull defect reconstruction with titanium mesh is one of the most challenging problems for plastic and reconstructive surgeons. Current approaches are disappointing. Methods In 10 patients, we explored the role of acellular dermal matrix (ADM) in combination with autologous skin grafts (ASGs) for closure of chronic wounds after skull reconstruction with titanium. Results ADM and ASG survived in all patients. Grade A healing (healing well without defect) was achieved. The average operating time was 30 to 45 minutes, and the average blood loss 30 to 50 mL. After 3 months, the wound was still closed in all patients. Conclusion The combination of ADM plus ASG obtained a high wound closure rate. ADM plus ASG allows avoiding other procedures such as rotational flaps and free flaps that require more operating time, special equipment, and adequate training.

19 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
NWNan Wu
Nan Wu
LLLusi Lu
Lusi Lu
YLYiming Liu
Yiming Liu
SHSunyue He
Sunyue He
CXChunyi Xu
Chunyi Xu
JZJiaqiang Zhou
Jiaqiang Zhou
Background: Ramulus Mori (Sangzhi) Alkaloids (SZ-A) are natural hypoglycemic compounds known to enhance insulin secretion. Given the emerging role of the gut microbiota in regulating β-cell function, in this study, we aimed to investigate whether SZ-A exert their beneficial effects through modulating the gut microbiota and its metabolites. Methods: A diabetic mouse model was established using a high-fat diet and streptozotocin, followed by 20 weeks of SZ-A treatment. Gut microbiota and metabolites were profiled via 16S rRNA sequencing and liquid chromatography–mass spectrometry, respectively. Spearman’s correlation analysis was used to explore associations between gut microbiota and metabolites. Single-cell RNA sequencing (scRNA-seq) was used to assess gene expression and signaling pathway changes in β cells. Results: Our results demonstrate that SZ-A alleviated hyperglycemia and increased islet numbers in T2DM mice. SZ-A treatment also reshaped the gut microbiota, notably enriching quantities of Lactobacillus and norank_f__Eubacterium_coprostanoligenes_group, which may contribute to increasing levels of 2-methoxyestradiol (2-ME), a bioactive metabolite. Moreover, scRNA-seq revealed an increased proportion of COMT+ cells in the islets, suggesting that 2-ME may also be synthesized within the islets. In vitro, 2-ME suppressed HIF-1α signaling and promoted insulin secretion, indicating that 2-ME may act as a crucial mediator of the beneficial effects of SZ-A. Conclusions: SZ-A improve β-cell function by increasing 2-ME levels via gut microbiota modulation and islet production, ultimately suppressing HIF-1α signaling and restoring β-cell homeostasis.

4 November 2025 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
LLLusi Lu
Lusi Lu
CGChenlu Gao
Chenlu Gao
NWNan Wu
Nan Wu
SHSunyue He
Sunyue He
YLYiming Liu
Yiming Liu
JZJiaqiang Zhou
Jiaqiang Zhou
Introduction: Hepatic fibrosis caused by metabolic dysfunction-associated steatotic liver disease (MASLD) predicts adverse atherosclerotic cardiovascular disease (ASCVD) outcomes in the general patient population. However, it is unclear whether this association extends to type 2 diabetes mellitus (T2DM) patients, who have distinct metabolic profiles and high comorbidity of both MASLD and ASCVD. To address this gap, we investigated the association between hepatic fibrosis caused by MASLD and ASCVD risk in T2DM patients as well as potentially moderators of this association. Research design and methods: This multisite cross-sectional study included 1238 hospitalized T2DM patients with MASLD (mean age=57.81±10.23, 37% female). Hepatic fibrosis was assessed via the Steatosis-Associated Fibrosis Estimator (SAFE) score, and 10-year ASCVD risk was assessed via the ASCVD Risk Calculator. Results: Advanced fibrosis was present in 25.6% of patients. Multivariable regression revealed a significant association between the SAFE score and 10-year ASCVD risk (p<0.001), after adjusting for covariates. Each unit increase in SAFE score was associated with 0.07-unit increase in 10-year ASCVD risk score. Increase in SAFE score was associated with greater increase in 10-year ASCVD risk score among patients with hypertension, insulin resistance and elevated low-density lipoprotein (LDL) cholesterol ( p s<0.05). Overweight/obesity, triglycerides, high-density lipoprotein cholesterol, uric acid, thyroid-stimulating hormone, hemoglobin A1c and high-sensitivity C reactive protein showed no moderating effects. Conclusions: In T2DM patients, hepatic fibrosis caused by MASLD is associated with elevated ASCVD risks, particularly among those with hypertension, insulin resistance and elevated LDL cholesterol. It is crucial to incorporate hepatic fibrosis assessment into ASCVD risk stratification in T2DM patients with comorbid MASLD to inform early prevention of ASCVD.

12 December 2022 in Research Square
Verified
Preprint
Open access
PDF file
SHSunyue He
Sunyue He
YZYuchen Zhao
Yuchen Zhao
GWGuoxing Wang
Guoxing Wang
QKQiaofang Ke
Qiaofang Ke
NWNan Wu
Nan Wu
JZJiaqiang Zhou
Jiaqiang Zhou
Background: Pancreatic beta cell dysfunction and activated macrophage infiltration are early features in type 1 diabetes pathogenesis. A tricarboxylic acid cycle metabolite that can strongly activate NF-E2-related factor 2 (Nrf2) in macrophages, itaconate is important in a series of inflammatory-associated diseases by anti-inflammatory and antioxidant properties. However, its role in type 1 diabetes is unclear. We used 4-octyl itaconate (OI), the cell-permeable itaconate derivate, to explore its preventative and therapeutic effects in mouse models of type 1 diabetes and the potential mechanism of macrophage phenotype reprogramming. Methods: The mouse model of streptozotocin (STZ) induced type 1 diabetes and spontaneous autoimmune diabetes were used to evaluate the preventative and therapeutic effects of OI, which were performed by measuring blood glucose, insulin level, pro- and anti-inflammatory cytokine secretion, histopathology examination, flow cytometry, and islet proteomics. The protective effect and mechanism of OI were further examined via peritoneal macrophages isolated from STZ-induced diabetic mice and co-cultured MIN6 cells with OI-pre-treated inflammatory macrophages in vitro. Moreover, the inflammatory status of peripheral blood mononuclear cells (PBMCs) from type 1 diabetes patients was evaluated after OI treatment. Results: OI ameliorated glycemic deterioration, increased systemic insulin level, and improved glucose metabolism in STZ-induced diabetic mice and non-obese diabetic (NOD) mice. Meanwhile, the islet insulitis and beta cell function were significantly restored by OI intervention. Indeed, OI did not change the count of macrophages but significantly downregulated the proportion of M1 macrophages. In addition, OI significantly inhibited MAPK activation in macrophages to attenuate the macrophage inflammatory response, eventually improving beta cell dysfunction in vitro. We also found higher IL-1β production upon lipopolysaccharide stimulation in the PBMCs from type 1 diabetes patients, which was attenuated by OI treatment. Conclusions: These results provided the first evidence to date that OI can prevent the progression of glycemic deterioration, excessive inflammation, and beta cell dysfunction predominantly mediated by restricting macrophage M1 polarization in mouse models of type 1 diabetes.

3 September 2026 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
WZWenjing Zhang
Wenjing Zhang
加吴加华 吴
加华 吴
YZYuchen Zhao
Yuchen Zhao
NWNan Wu
Nan Wu
SSShuiya Sun
Shuiya Sun
JZJiaqiang Zhou
Jiaqiang Zhou